Annexon Launches New Immunotherapies to Improve Neuroinflammation Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 30 2026
0mins
Should l Buy ANNX?
"We're energized by this defining period for Annexon. Two decades of C1q and classical complement pathway research have enabled our bold mission of pioneering a new class of targeted immunotherapies that reshape how neuroinflammation is treated. Today, our scientific platform has translated into two late stage registrational programs with the potential to improve the lives of millions in large, underserved markets worldwide," said Douglas Love, president and chief executive officer of Annexon. "Leveraging one mechanism to stop neuroinflammation at its source, vonaprument is designed to protect photoreceptor neurons to preserve vision in GA, while tanruprubart is designed to protect peripheral nerves to support faster, more complete and durable recovery in GBS."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ANNX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ANNX
Wall Street analysts forecast ANNX stock price to rise
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 5.690
Low
8.00
Averages
16.40
High
27.00
Current: 5.690
Low
8.00
Averages
16.40
High
27.00
About ANNX
Annexon, Inc. is a clinical-stage biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye. It identifies and characterizes the role of the classical complement pathway in three therapeutic areas: autoimmune, neurodegeneration and ophthalmology, using its proprietary platform. Its lead candidate, ANX005, an investigational, full-length monoclonal antibody (mAb), is formulated for intravenous administration as the potential first targeted treatment for patients with Guillain-Barre Syndrome (GBS). It is advancing ANX1502, a novel small-molecule inhibitor of classical complement designed for oral administration in a range of chronic autoimmune diseases. It is also advancing ANX007, designed to block C1q locally in the eye, to provide complete protection against excess classical complement activity and the loss of photoreceptor neurons.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
GBS|CIDP Awareness Month: Celebrating 110 Years of Advocacy
- Historical Milestone: This year marks the 110th anniversary of the discovery of Guillain-Barré syndrome (GBS), highlighting that despite over a century of research, thousands still face the challenges posed by this condition each year, indicating a continued need for awareness and research.
- Story Sharing Initiative: The GBS|CIDP Foundation International has launched the 'GBS: 110 Years, 110 Stories' campaign, aiming to share 110 stories from GBS patients worldwide through short videos to raise public awareness and understanding of this rare disease.
- Partnership for Awareness: The GBS|CIDP Foundation International has partnered with Annexon Biosciences to promote the GBS 110 campaign, with the goal of gathering and showcasing 110 patient stories to emphasize the urgent need for advancements in patient care.
- Impact Statistics: According to the GBS|CIDP Foundation International, GBS affects approximately 2 in 100,000 people annually, while the prevalence of CIDP is estimated to be as high as 9 in 100,000, underscoring the rarity of these conditions and their profound impact on patients' lives.
See More
GBS|CIDP Awareness Month: 110 Years of Progress and Future Goals
- Historical Milestone: This year marks the 110th anniversary of the discovery of Guillain-Barré syndrome (GBS), highlighting over a century of global research and awareness efforts since its identification by French neurologists in 1916, despite ongoing challenges faced by thousands of patients.
- Story Sharing Initiative: The GBS|CIDP Foundation International has launched the 'GBS: 110 Years, 110 Stories' campaign to raise awareness of GBS and CIDP by collecting 110 patient stories from around the world, encouraging individuals to share their experiences to build a stronger support network.
- Partnership for Awareness: The campaign collaborates with Annexon Biosciences to emphasize the urgent need for improved care for GBS patients through storytelling, with Annexon's VP noting the inspiring resilience of GBS survivors despite long-term impacts of the disease.
- Disease Prevalence: GBS affects approximately 2 in 100,000 people annually, while the prevalence of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is estimated at 9 in 100,000, underscoring the necessity for continued focus and research on these rare conditions.
See More
Annexon Biosciences Q1 Earnings Beat Expectations
- Earnings Performance: Annexon Biosciences reported a Q1 GAAP EPS of -$0.23, beating expectations by $0.06, indicating improvements in financial management and operational efficiency.
- Strong Balance Sheet: As of March 31, 2026, the company holds approximately $225 million in cash, cash equivalents, and short-term investments, providing a financial runway into the second half of 2027, which enhances investor confidence in its sustainability.
- C1q Inhibition Research Progress: Annexon is advancing research on C1q inhibition for vision preservation in geographic atrophy, leveraging key insights from the ARCHER trials, showcasing its innovative potential in ophthalmic treatments.
- Historical Financial Data Review: Historical earnings data indicates that despite challenges, Annexon Biosciences is gradually improving its financial performance, reflecting its adaptability and growth potential in the biopharmaceutical industry.
See More
Annexon and Exzeo Executives Increase Stock Holdings
- Carson's ANNX Purchase: William H. Carson bought 8,000 shares of ANNX at $6.20 each on Friday, totaling $49,600, which brings his total investment over the past year to $138,729 at an average cost of $3.77 per share, indicating strong confidence in the company's future.
- ANNX Stock Surge: Following Carson's purchase, ANNX shares rose approximately 6% on Wednesday, reflecting positive market sentiment towards insider buying, which may further bolster investor confidence in the company's prospects.
- Patel's XZO Investment: Exzeo Group CEO Paresh Patel purchased 2,000 shares of XZO at $15.13 each on Monday for a total of $30,260, increasing his total investment over the past year to $1.41 million at an average price of $19.02 per share, demonstrating optimism about the company's long-term value.
- XZO Stock Performance: Patel's recent purchase has led to a 1.3% increase in XZO's stock price on Wednesday, with his investment currently yielding an approximate 8.8% gain based on the day's high of $16.45, indicating growing market confidence in Exzeo.
See More
Annexon Biosciences Q4 Earnings Beat Expectations
- Earnings Highlights: Annexon Biosciences reported a Q4 GAAP EPS of -$0.28, beating expectations by $0.04, indicating improvements in financial management despite ongoing losses.
- Cash Position: As of December 31, 2025, the company held $238.3 million in cash, cash equivalents, and short-term investments, including $86.3 million from a November 2025 public offering, ensuring operational funding for the coming years.
- Investment Strategy: Annexon plans to focus investments on its lead late-stage programs, expecting to fund operations and anticipated milestones into the second half of 2027, reflecting confidence in future growth.
- Market Outlook: The company is viewed as a high-risk, high-reward investment opportunity in a new approach to complement-mediated diseases, particularly in vision preservation for geographic atrophy, which may attract increased investor interest in its R&D progress.
See More
ANNEXON INC: EXPECTED CASH RESOURCES TO LAST THROUGH THE SECOND HALF OF 2027
- Anticipated Cash Runway: The company expects a cash runway extending into the second half of 2027.
- Financial Outlook: This projection indicates a stable financial position and potential for continued operations without immediate funding needs.
See More
GBS|CIDP Awareness Month: Celebrating 110 Years of Advocacy
- Historical Milestone: This year marks the 110th anniversary of the discovery of Guillain-Barré syndrome (GBS), highlighting that despite over a century of research, thousands still face the challenges posed by this condition each year, indicating a continued need for awareness and research.
- Story Sharing Initiative: The GBS|CIDP Foundation International has launched the 'GBS: 110 Years, 110 Stories' campaign, aiming to share 110 stories from GBS patients worldwide through short videos to raise public awareness and understanding of this rare disease.
- Partnership for Awareness: The GBS|CIDP Foundation International has partnered with Annexon Biosciences to promote the GBS 110 campaign, with the goal of gathering and showcasing 110 patient stories to emphasize the urgent need for advancements in patient care.
- Impact Statistics: According to the GBS|CIDP Foundation International, GBS affects approximately 2 in 100,000 people annually, while the prevalence of CIDP is estimated to be as high as 9 in 100,000, underscoring the rarity of these conditions and their profound impact on patients' lives.
See More
GBS|CIDP Awareness Month: 110 Years of Progress and Future Goals
- Historical Milestone: This year marks the 110th anniversary of the discovery of Guillain-Barré syndrome (GBS), highlighting over a century of global research and awareness efforts since its identification by French neurologists in 1916, despite ongoing challenges faced by thousands of patients.
- Story Sharing Initiative: The GBS|CIDP Foundation International has launched the 'GBS: 110 Years, 110 Stories' campaign to raise awareness of GBS and CIDP by collecting 110 patient stories from around the world, encouraging individuals to share their experiences to build a stronger support network.
- Partnership for Awareness: The campaign collaborates with Annexon Biosciences to emphasize the urgent need for improved care for GBS patients through storytelling, with Annexon's VP noting the inspiring resilience of GBS survivors despite long-term impacts of the disease.
- Disease Prevalence: GBS affects approximately 2 in 100,000 people annually, while the prevalence of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is estimated at 9 in 100,000, underscoring the necessity for continued focus and research on these rare conditions.
See More
Annexon Biosciences Q1 Earnings Beat Expectations
- Earnings Performance: Annexon Biosciences reported a Q1 GAAP EPS of -$0.23, beating expectations by $0.06, indicating improvements in financial management and operational efficiency.
- Strong Balance Sheet: As of March 31, 2026, the company holds approximately $225 million in cash, cash equivalents, and short-term investments, providing a financial runway into the second half of 2027, which enhances investor confidence in its sustainability.
- C1q Inhibition Research Progress: Annexon is advancing research on C1q inhibition for vision preservation in geographic atrophy, leveraging key insights from the ARCHER trials, showcasing its innovative potential in ophthalmic treatments.
- Historical Financial Data Review: Historical earnings data indicates that despite challenges, Annexon Biosciences is gradually improving its financial performance, reflecting its adaptability and growth potential in the biopharmaceutical industry.
See More
Annexon and Exzeo Executives Increase Stock Holdings
- Carson's ANNX Purchase: William H. Carson bought 8,000 shares of ANNX at $6.20 each on Friday, totaling $49,600, which brings his total investment over the past year to $138,729 at an average cost of $3.77 per share, indicating strong confidence in the company's future.
- ANNX Stock Surge: Following Carson's purchase, ANNX shares rose approximately 6% on Wednesday, reflecting positive market sentiment towards insider buying, which may further bolster investor confidence in the company's prospects.
- Patel's XZO Investment: Exzeo Group CEO Paresh Patel purchased 2,000 shares of XZO at $15.13 each on Monday for a total of $30,260, increasing his total investment over the past year to $1.41 million at an average price of $19.02 per share, demonstrating optimism about the company's long-term value.
- XZO Stock Performance: Patel's recent purchase has led to a 1.3% increase in XZO's stock price on Wednesday, with his investment currently yielding an approximate 8.8% gain based on the day's high of $16.45, indicating growing market confidence in Exzeo.
See More
Annexon Biosciences Q4 Earnings Beat Expectations
- Earnings Highlights: Annexon Biosciences reported a Q4 GAAP EPS of -$0.28, beating expectations by $0.04, indicating improvements in financial management despite ongoing losses.
- Cash Position: As of December 31, 2025, the company held $238.3 million in cash, cash equivalents, and short-term investments, including $86.3 million from a November 2025 public offering, ensuring operational funding for the coming years.
- Investment Strategy: Annexon plans to focus investments on its lead late-stage programs, expecting to fund operations and anticipated milestones into the second half of 2027, reflecting confidence in future growth.
- Market Outlook: The company is viewed as a high-risk, high-reward investment opportunity in a new approach to complement-mediated diseases, particularly in vision preservation for geographic atrophy, which may attract increased investor interest in its R&D progress.
See More
ANNEXON INC: EXPECTED CASH RESOURCES TO LAST THROUGH THE SECOND HALF OF 2027
- Anticipated Cash Runway: The company expects a cash runway extending into the second half of 2027.
- Financial Outlook: This projection indicates a stable financial position and potential for continued operations without immediate funding needs.
See More
